ADC Linker

DBCO-PEG4-Val-Ala-PAB is a cleavable ADC linker that effectively targets Cathepsin B for linker cleavage. The incorporation of Val-Ala linkers facilitates the controlled release of therapeutic agents, enhancing the efficacy of antibody-drug conjugates (ADCs). The DBCO moiety enables efficient Click Chemistry reactions, while the PEG spacer enhances the aqueous solubility of the compound, making it suitable for various biochemical applications.

Fmoc-Gly-Thr-OH is a synthetic linker commonly utilized in the development of antibody-drug conjugates (ADCs). This compound facilitates the conjugation of antibodies with cytotoxic drugs, enhancing targeted delivery to cancer cells. It plays a crucial role in pharmaceutical research focused on improving the efficacy and selectivity of therapeutic agents in cancer treatment.

N3-PEG5-aldehyde is a cleavable linker designed for use in antibody-drug conjugates (ADCs), featuring a five-unit polyethylene glycol (PEG) structure. This compound contains an azide functional group, enabling its application in click chemistry through copper-catalyzed azide-alkyne cycloaddition (CuAAc) with alkyne-containing molecules. Additionally, it is capable of participating in strain-promoted azide-alkyne cycloaddition (SPAAC) reactions with dibenzocyclooctyne (DBCO) or bicyclononyne (BCN) groups. N3-PEG5-aldehyde is valuable in the development of targeted therapeutics, enhancing drug delivery and efficacy.

Ald-Ph-amido-PEG3-C1-Boc is a polyethylene glycol (PEG) linker designed for antibody-drug conjugate (ADC) applications. This compound facilitates the conjugation of cytotoxic agents to antibodies, enhancing the selectivity and efficacy of targeted therapies. It operates by linking the drug payload to an antibody through a stable amide bond, which is critical for the development and optimization of ADCs in cancer research.

Mal-PEG4-bis-PEG3-DBCO is a cleavable linker designed for use in antibody-drug conjugates (ADCs), facilitating targeted delivery of therapeutics. This reagent features a DBCO group that enables strain-promoted alkyne-azide cycloaddition (SPAAC) with azide-containing molecules, allowing for efficient conjugation. Its PEGylated structure enhances solubility and provides stability in biological applications, making it suitable for ADC development and related research endeavors.

MC-Gly-Gly-Phe-Boc is a versatile ADC linker that facilitates the synthesis of antibody-drug conjugates, specifically with Trastuzumab. This compound plays a crucial role in cancer research by enabling targeted delivery of therapeutic agents, thereby enhancing the efficacy of cancer treatment. Its unique structure supports the development of advanced therapeutic strategies aimed at improving patient outcomes in oncology.

Me-Tet-PEG9-NHS is an antibody-drug conjugate (ADC) linker featuring a 9-unit polyethylene glycol (PEG) chain. This reagent enables a specific inverse electron demand Diels-Alder (iEDDA) reaction with trans-cyclooctene (TCO) functionalized compounds, facilitating targeted delivery of therapeutic agents. Its unique properties make it suitable for applications in the development of novel ADCs in cancer research and targeted therapies.

m-PEG5-MS is a PEG-based linker designed for antibody-drug conjugates (ADCs) and proteolysis-targeting chimeras (PROTACs). This cleavable linker facilitates the synthesis of PROTACs, enabling targeted degradation of specific proteins. Its key applications include drug development and cellular regulation studies, making it a versatile tool in therapeutic research and protein modulation.

Boc-Gly-Gly-Phe-Gly-OH TFA is a protease-cleavable linker designed for use in antibody-drug conjugates (ADCs). This self-assembling tetrapeptide features N- and C-terminal protection, facilitating targeted drug delivery. Its key biological activity includes enabling specific cleavage by proteases, thus enhancing the release of therapeutic agents in the desired cellular environment. This reagent is essential for researchers developing innovative ADC platforms in cancer therapy.

DBCO-PEG3 acetic-EVCit-PAB is a cleavable ADC linker that features a three-unit polyethylene glycol (PEG) chain. This compound facilitates the construction of antibody-drug conjugates (ADCs) by employing click chemistry through its dibenzocyclooctyne (DBCO) moiety, which engages in strain-promoted alkyne-azide cycloaddition (SPAAC) with azide-containing molecules. DBCO-PEG3 acetic-EVCit-PAB is integral in enhancing the specificity and efficacy of therapeutic agents in targeted cancer treatments, making it a valuable tool for bioconjugation research.

ALD-PEG4-OPFP is a cleavable polyethylene glycol (PEG) linker designed for antibody-drug conjugate (ADC) synthesis. This four-unit PEG linker facilitates the covalent attachment of cytotoxic drugs to antibodies, promoting targeted delivery and enhanced therapeutic efficacy. ALD-PEG4-OPFP is valuable for research applications focusing on ADC development, enabling the study of drug release and optimizing therapeutic strategies.

Amino-PEG11-OH is a non-cleavable linker composed of an 11-unit polyethylene glycol (PEG) moiety designed for use in antibody-drug conjugates (ADCs) and PROTAC (Proteolysis Targeting Chimera) synthesis. This PEG-based linker facilitates the conjugation of drugs to antibodies, enhancing therapeutic efficacy while maintaining stability. Additionally, it serves as an effective component in the development of PROTACs, enabling targeted protein degradation for advanced molecular research applications.

Boc-Phe-(Alloc)Lys-PAB-PNP is a cleavable linker designed for use in antibody-drug conjugates (ADCs). This compound facilitates the selective release of cytotoxic agents upon internalization of the ADC, enhancing therapeutic efficacy while minimizing off-target effects. Its application is critical in the development of targeted cancer therapies, allowing for the precise delivery of drugs to tumor cells.

Boc-C2-Urea-bis(Boc)-C4-Urea-4-phenylacetic acid is a cleavable linker specifically designed for the synthesis of antibody-drug conjugates (ADCs). This compound facilitates the stable attachment of cytotoxic agents to antibodies, allowing for targeted therapy applications in cancer research. Its unique structure promotes selective release of the drug once internalized by target cells, enhancing therapeutic efficacy while minimizing off-target effects.

DBCO-PEG4-alkyne is a non-cleavable linker designed for antibody-drug conjugates (ADCs), featuring a 4-unit polyethylene glycol (PEG) chain. This compound serves as a versatile click chemistry reagent, incorporating an alkyne functional group that enables the efficient copper-catalyzed azide-alkyne cycloaddition (CuAAc) with azide-containing molecules. Its application in ADC synthesis facilitates the stable conjugation of therapeutic agents, enhancing the efficacy and selectivity of targeted cancer treatments.

Azidoethyl-SS-propionic NHS ester is a cleavable linker specifically designed for the synthesis of antibody-drug conjugates (ADCs). This compound features an azide functional group, enabling it to participate in click chemistry reactions, including copper-catalyzed azide-alkyne cycloaddition (CuAAc) with alkyne-containing molecules. Additionally, it can engage in strain-promoted alkyne-azide cycloaddition (SPAAC) with DBCO or BCN functionalities, making it a versatile tool for bioconjugation applications in chemical biology and targeted therapeutics.

Mal-PEG4-VC-PAB-DMEA is a cleavable linker featuring a Maleimide moiety utilized in the design of antibody-drug conjugates (ADCs). This compound facilitates the selective conjugation of cytotoxic agents to antibodies, enhancing targeted delivery to specific cancer cells. Its inherent stability and designed release mechanism make it a valuable tool for researchers developing ADCs in therapeutic and diagnostic applications.

Val-Cit-PABC-Ahx-May is a cleavable linker designed for use in antibody-drug conjugates (ADCs). It facilitates the selective release of therapeutics upon internalization by target cells, enhancing the efficacy of targeted cancer therapies. This linker is utilized in research applications focused on the development and optimization of ADCs for improved pharmacokinetics and therapeutic outcomes.

Propargyl-PEG1-SS-PEG1-propargyl is a cleavable linker designed for use in the synthesis of antibody-drug conjugates (ADCs). This PEG-based reagent features an alkyne functionality, enabling its participation in copper-catalyzed azide-alkyne cycloaddition (CuAAC) reactions with azide-containing molecules. It is particularly useful for developing targeted therapeutics, facilitating the stable attachment of cytotoxic agents to antibodies while maintaining drug efficacy and specificity.

Biotin-sar-oh is a cleavable linker designed for use in the synthesis of antibody-drug conjugates (ADCs). It facilitates targeted delivery of cytotoxic agents by linking antibodies to drug molecules, enabling selective cancer cell targeting. This compound is essential for researchers focusing on ADC development and optimization, enhancing therapeutic efficacy while minimizing off-target effects.

Bis-PEG1-PFP ester is a non-cleavable linker designed for antibody-drug conjugate (ADC) synthesis, featuring a single unit of polyethylene glycol (PEG). This reagent facilitates the conjugation of antibodies with cytotoxic agents, maintaining stability during circulation. Its unique properties make it suitable for enhancing the therapeutic efficacy of ADCs while minimizing off-target effects, making it invaluable for cancer research and drug development.

(R)-8-Azido-2-(Fmoc-amino)octanoic acid is a non-cleavable linker for antibody-drug conjugates (ADCs), facilitating the synthesis of targeted therapeutics. This compound features an azide functional group, enabling it to participate in copper-catalyzed azide-alkyne cycloaddition (CuAAc) reactions with alkyne-containing molecules. Additionally, it can engage in strain-promoted alkyne-azide cycloaddition (SPAAC) with entities that possess DBCO or BCN functionalities, making it a versatile tool in chemical biology and medicinal chemistry applications.

NO2-SPP-sulfo-Me is a cleavable linker designed for use in antibody-drug conjugates (ADCs). This reagent facilitates the attachment of cytotoxic agents to antibodies, enhancing targeted delivery to cancerous cells. Its unique structure allows for controlled release of the drug upon internalization, making it a valuable tool in cancer research and therapeutic development.

BCOT-PEF3-OPFP is a cleavable linker designed for the synthesis of antibody-drug conjugates (ADCs). This compound features an alkyne group that facilitates the copper-catalyzed azide-alkyne cycloaddition (CuAAc) reaction with azide-containing molecules. Its application in ADC development allows for enhanced targeting and controlled release of therapeutic agents, making it a valuable tool in cancer research and therapeutic applications.

MC-PEG2-NH2 is a cleavable linker designed for use in the synthesis of antibody-drug conjugates (ADCs). This reagent facilitates the conjugation of antibodies to cytotoxic drugs, enabling targeted delivery and enhancing therapeutic efficacy. Its unique structure provides stability in circulation while allowing for controlled release of the drug within the target cells, making it valuable for research in targeted cancer therapies and bioconjugate development.

Val-Cit-PABC-Ahx-May TFA is a cleavable linker designed for use in the construction of antibody-drug conjugates (ADCs). This compound facilitates targeted drug delivery, allowing for the selective release of therapeutic agents upon internalization by cancer cells. It is particularly valuable in research applications focused on optimizing ADC formulations and enhancing therapeutic efficacy.

Bromoacetamide-PEG4-DBCO is an efficient ADC linker that facilitates the synthesis of antibody-drug conjugates. This compound features a bromoacetamide moiety for selective labeling and a DBCO group for click chemistry applications. It is ideal for enhancing the therapeutic efficacy of targeted cancer treatments by enabling stable conjugation to antibodies. This linker is suitable for a variety of research applications focused on drug delivery systems and cancer therapeutics.

Propargyl-NH-PEG3-C2-NHS ester is a non-cleavable linker designed for the synthesis of antibody-drug conjugates (ADCs). This reagent features a propargyl group, enabling it to participate in copper-catalyzed azide-alkyne cycloaddition (CuAAc) with azide-containing molecules. Its unique properties make it a valuable tool for developing targeted therapies in cancer research and drug delivery systems.

Propargyl-PEG7-NHS ester is a PEG-based linker designed for use in the synthesis of PROTACs and antibody-drug conjugates (ADCs). This cleavable linker features an alkyne group, facilitating copper-catalyzed azide-alkyne cycloaddition (CuAAc) with azide-containing molecules. Its versatility and efficiency make it a valuable tool in the development of targeted therapeutics and bioconjugates for cancer research and drug delivery applications.

BCN-PEG4-HyNic is a cleavable linker designed for antibody-drug conjugate (ADC) synthesis, featuring a four-unit polyethylene glycol (PEG) spacer. Its primary mechanism involves click chemistry, specifically through the strain-promoted alkyne-azide cycloaddition (SPAAC) reaction, which facilitates the conjugation of azide-containing biomolecules. This reagent is ideal for researchers developing targeted therapeutics, enabling enhanced delivery and reduced systemic toxicity of cytotoxic drugs in cancer therapy.

Mal-PEG4-VCP-NB is a degradable antibody-drug conjugate (ADC) linker featuring a maleimide moiety, four polyethylene glycol (PEG) units, and a valproyl carbamate (VCP) nitrobenzyl (NB) group. This compound facilitates efficient conjugation to thiol-containing molecules, thereby enhancing drug delivery to targeted cells. Mal-PEG4-VCP-NB is particularly valuable in the development of ADCs for cancer research, enabling precise therapeutic applications by allowing controlled release of cytotoxic agents in the tumor microenvironment.

MC-GGFG-NH-D-Lactic acid functions as an effective linker for antibody-drug conjugate (ADC) applications. This compound is designed to facilitate the conjugation of therapeutic agents to antibodies, enhancing the delivery and efficacy of targeted therapies. Its structural properties make it suitable for use in the development of innovative drugs aimed at improving cancer treatment outcomes.

Me-Tet-PEG2-COOH is an ADC linker featuring two PEG units and a tetrazine moiety. It facilitates a specific inverse electron demand Diels-Alder reaction (iEDDA) with trans-cyclooctene (TCO) derivatives, enabling efficient conjugation in antibody-drug conjugate (ADC) applications. This reagent is ideal for researchers aiming to enhance the targeting and delivery of therapeutic agents in cancer treatment and other bioconjugation studies.

Hydroxy-PEG10-Boc is an uncleavable linker specifically designed for the synthesis of antibody-drug conjugates (ADCs). This reagent facilitates the conjugation of cytotoxic agents, such as Paclitaxel and Docetaxel, to antibodies, enhancing targeted delivery and therapeutic efficacy in cancer research. Its stability and biocompatibility make it a valuable tool for the development of innovative ADC formulations.

(2-pyridyldithio)-PEG4 acid is a cleavable polyethylene glycol (PEG) linker designed for use in antibody-drug conjugates (ADCs). This four-unit PEG linker facilitates the conjugation of therapeutic agents to antibodies, enabling controlled release and targeted delivery of drugs. Its unique properties enhance the stability and efficacy of ADCs, making it a valuable tool for research in targeted cancer therapies and other therapeutic applications.

Azido-C2-SS-PEG2-C2-acid is a cleavable polyethylene glycol (PEG) linker designed for use in antibody-drug conjugates (ADCs). It features an azide group that allows for copper-catalyzed azide-alkyne cycloaddition (CuAAc) with alkyne-containing molecules. Additionally, this linker can participate in strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with DBCO or BCN-modified compounds, enabling versatile bioconjugation applications in chemical biology and therapeutic development.

PDP-C1-Ph-Val-Cit is a cleavable linker specifically designed for antibody-drug conjugates (ADCs). This compound facilitates the selective release of cytotoxic agents in targeted cancer therapy, enhancing the efficacy of ADCs while minimizing off-target effects. Its unique structure allows for stable attachment to antibodies while ensuring effective drug release in the tumor microenvironment, making it a valuable tool in cancer research and therapeutic development.

NO2-SPDMV-sulfo is a cleavable linker designed for use in the synthesis of antibody-drug conjugates (ADCs). This compound facilitates selective attachment of therapeutic agents to antibodies, enhancing targeted delivery while minimizing systemic toxicity. Its chemical structure allows for effective release of the drug payload upon reaching the target site, making it valuable in cancer research and therapeutic development.

NHPI-PEG2-C2-Pfp ester is a non-cleavable linker designed for the synthesis of antibody-drug conjugates (ADCs). This 2-unit PEG-based linker facilitates stable covalent attachment between antibodies and cytotoxic drugs, enhancing the therapeutic efficacy while minimizing systemic toxicity. Its unique structure allows for improved solubility and bioavailability, making it a valuable component in ADC development and research applications.

Fmoc-GGFG-PAB-PNP is a novel ADC linker designed to facilitate the synthesis of antibody-drug conjugates (ADCs). This compound promotes the effective delivery of cytotoxic agents directly to target cells, enhancing therapeutic efficacy while minimizing off-target effects. It is instrumental in research applications focused on developing targeted cancer therapies and improving drug delivery systems in biomedical research.

N-Boc-N-bis(PEG2-OH) is a PEG-based linker designed for use in antibody-drug conjugates (ADCs) and PROTAC synthesis. This cleavable linker facilitates the precise attachment of therapeutic agents to antibodies, enhancing targeted drug delivery while minimizing off-target effects. Its structure allows for efficient conjugation and release of the active component, making it suitable for a variety of applications in drug development and molecular biology research.

Amino-ethyl-SS-PEG3-NHBoc is a cleavable linker featuring a three-unit polyethylene glycol (PEG) structure, designed for use in the synthesis of antibody-drug conjugates (ADCs). This compound facilitates the attachment of cytotoxic agents to antibodies, allowing for targeted delivery and enhanced therapeutic efficacy. Its cleavable nature enables the release of the therapeutic agent in the tumor microenvironment, making it a valuable tool for cancer research and drug development.

Val-Cit-PAB-DEA-COOH is an ADC linker designed for use in the synthesis of antibody-drug conjugates (ADCs). Its structure facilitates the controlled release of cytotoxic agents upon internalization by target cells, enhancing the specificity and efficacy of therapeutic applications. This compound is valuable in research focused on developing novel ADCs for cancer therapy.

mDPR(Boc)-Val-Cit-PAB is a cleavable linker specifically designed for antibody-drug conjugates (ADCs). It features a unique mechanism that facilitates the release of cytotoxic agents upon cellular internalization. This compound plays a critical role in enhancing the therapeutic efficacy of ADCs by improving selective drug delivery to targeted cancer cells. Its utility makes it a valuable reagent in cancer research and the development of targeted therapies.

Aminoethyl-SS-ethylalcohol is a glutathione-cleavable linker specifically designed for the synthesis of antibody-drug conjugates (ADCs). This reagent facilitates the release of cytotoxic agents in targeted therapy, ensuring selective delivery to cancer cells. Its biological activity contributes to the development of effective therapeutic strategies in cancer research and drug development.

Methylcyclopropene-PEG3-amine is a cleavable linker designed for the synthesis of antibody-drug conjugates (ADCs). This three-unit polyethylene glycol (PEG) derivative facilitates the attachment of therapeutic agents to antibodies, enhancing the specificity and efficacy of ADCs. It has applications in cancer research and drug delivery systems, allowing for targeted therapy while minimizing off-target effects.

Di(4-morpholine-amide)-4-DTM-phenoxy(3,5-F)-O-PEG3-CH2COOH functions as a cleavable PEG-based linker for antibody-drug conjugates (ADCs). This compound facilitates the attachment of cytotoxic agents to antibodies while maintaining stability in circulation and enabling targeted delivery. Its strategic design enhances drug release in the targeted cellular environment, making it invaluable for research in cancer therapeutics and ADC development.

Biotin-PEG3-Me-Tet is an ADC linker characterized by the inclusion of three polyethylene glycol (PEG) units. This compound features a tetrazine group that enables a specific inverse electron demand Diels-Alder reaction (iEDDA) with trans-cyclooctene (TCO) derivatives. Biotin-PEG3-Me-Tet is particularly valuable in antibody-drug conjugate (ADC) research, facilitating targeted delivery and enhancing the therapeutic efficacy of biologically active compounds.

THP-SS-alcohol is a cleavable ADC linker designed for the synthesis of antibody-drug conjugates (ADCs). Its unique structure facilitates the stable attachment of drug molecules to antibodies while enabling selective release in the target environment. This compound is essential for enhancing the efficacy and specificity of ADCs in cancer research and therapeutic applications.

N3-PEG2-C2-PFP ester is a non-cleavable linker designed for the synthesis of antibody-drug conjugates (ADCs), targeting effective conjugation in drug delivery systems. This reagent features an azide group that facilitates copper-catalyzed azide-alkyne cycloaddition (CuAAc) with alkyne-containing molecules and supports strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with DBCO or BCN functionalized compounds. Its versatility and stability make it an essential tool for researchers developing advanced therapeutic agents.